Nasdaq Issues Delisting Warnings to Aptorum and DeFi Technologies
Key Takeaways
- Aptorum and DeFi Technologies have received formal deficiency notices from Nasdaq for failing to maintain the $1.00 minimum bid price requirement.
- Both companies now face a 180-day deadline to regain compliance or risk being delisted to the over-the-counter markets.
Key Intelligence
Key Facts
- 1Notices issued on March 6, 2026, for failing to meet the $1.00 minimum bid price requirement.
- 2Both companies have a 180-day grace period to regain compliance with Nasdaq Listing Rule 5550(a)(2).
- 3Compliance requires a closing bid price of $1.00 or higher for 10 consecutive business days.
- 4Potential 'cures' include organic price recovery or a board-approved reverse stock split.
- 5Failure to comply by the September 2026 deadline could lead to delisting and a move to the OTC markets.
| Metric | ||
|---|---|---|
| Sector | Biotechnology | Fintech/Crypto |
| Notice Date | March 6, 2026 | March 6, 2026 |
| Compliance Deadline | Sept 2, 2026 (Est.) | Sept 2, 2026 (Est.) |
| Primary Risk | Clinical Trial Volatility | Crypto Market Correlation |
Analysis
The Nasdaq Stock Market has issued deficiency notices to two distinct small-cap entities, Aptorum Group Limited (APM) and DeFi Technologies Inc. (DEFI), for failing to maintain the minimum bid price of $1.00 per share. These notices, issued on March 6, 2026, underscore the persistent challenges faced by high-growth, high-risk sectors like biotechnology and decentralized finance in maintaining public listing standards during periods of market volatility. For both companies, the 180-day compliance clock has officially begun, forcing management to consider strategic maneuvers to avoid a transition to the over-the-counter (OTC) markets.
Nasdaq Listing Rule 5550(a)(2) is a fundamental requirement designed to ensure that listed companies maintain a baseline of liquidity and investor interest. When a stock's closing bid price falls below $1.00 for 30 consecutive business days, the exchange triggers a deficiency notice. While this does not result in immediate delisting, it serves as a formal warning that the company’s listing status is in jeopardy. Both Aptorum and DeFi Technologies now have until early September 2026 to regain compliance, which requires the closing bid price to reach at least $1.00 for a minimum of 10 consecutive business days.
Both Aptorum and DeFi Technologies now have until early September 2026 to regain compliance, which requires the closing bid price to reach at least $1.00 for a minimum of 10 consecutive business days.
Aptorum Group, a clinical-stage biopharmaceutical company, finds itself in a familiar position for many micro-cap biotech firms. The sector is notoriously capital-intensive, with long R&D cycles and binary outcomes from clinical trials that often lead to significant share price erosion if milestones are missed or delayed. For Aptorum, the challenge lies in generating enough positive clinical data or securing a strategic partnership within the next six months to drive organic buying pressure. If the market does not respond to fundamental developments, the company may be forced to implement a reverse stock split—a move often viewed with skepticism by retail investors as it can signal a lack of confidence in organic growth.
Conversely, DeFi Technologies represents the intersection of traditional finance and the digital asset economy. Its share price is frequently a proxy for broader sentiment in the cryptocurrency market. Despite the growth of institutional interest in digital assets, the company’s failure to maintain the $1.00 threshold suggests that investors remain cautious about the long-term viability of mid-tier crypto infrastructure plays. For DeFi Technologies, regaining compliance may depend less on internal operational milestones and more on a sustained rally in the underlying crypto market or a successful expansion of its exchange-traded product (ETP) offerings.
What to Watch
The implications of a potential delisting are severe for both companies. Moving to the OTC markets typically results in a significant reduction in trading volume, wider bid-ask spreads, and a loss of institutional coverage. Furthermore, many institutional mandates prohibit the holding of non-exchange-listed securities, which could trigger forced selling and further depress prices. To mitigate this, companies often seek a second 180-day extension if they meet other listing requirements, such as the market value of publicly held shares, and provide written notice of their intent to cure the deficiency, often through a reverse split.
Investors should watch for upcoming SEC filings from both APM and DEFI regarding their compliance plans. While a reverse split is a mechanical fix that satisfies the $1.00 requirement, it does not address the underlying valuation concerns. The true test for both Aptorum and DeFi Technologies will be whether they can leverage this 180-day window to demonstrate fundamental value that attracts sustainable capital, rather than relying solely on corporate actions to maintain their Nasdaq status.
How we covered this story
Every story in our finance coverage is assembled from multiple primary sources, cross-referenced for factual consistency, and scored along three independent dimensions: sentiment, operational impact, and source-cluster confidence. Single-source rumors and unverifiable claims do not pass our editorial gate. When a story shows "Verified by N sources" with N≥2, the development is independently corroborated; when N=1, we mark it explicitly so readers can weigh the signal accordingly.
Impact scoring uses a 1-10 scale weighted toward regulatory, financial, and operational consequence rather than coverage volume. A topic that runs in every outlet but moves no real decisions ranks lower than a niche regulatory filing that reshapes how operators in the finance space have to behave. Read our full methodology for the scoring rubric, our glossary for term definitions, and our trends index for the longitudinal view across the beat.
| Signal on this page | What it tells you |
|---|---|
| Verified by N sources | Independent corroboration count. N≥2 is our confidence floor; N=1 is marked explicitly. |
| Impact score (1-10) | Regulatory + financial + operational weight. 8+ signals an experienced-operator action item. |
| Sentiment | Five-tier classification trained on labeled finance-specific corpora. |
| Timeline | Where applicable, the related-events sequence that contextualizes today's development. |